The cost of asthma control
Asthma care has advanced significantly. This is attributed to a better understanding of clinical disease phenotypes and overlapping molecular endotypes amenable to therapy. Despite improvements inasthma care, rates of asthma control remain suboptimal. Adult asthma rates in Asia are lower than that in...
מחבר ראשי: | Chotirmall, Sanjay Haresh |
---|---|
מחברים אחרים: | Lee Kong Chian School of Medicine (LKCMedicine) |
פורמט: | Journal Article |
שפה: | English |
יצא לאור: |
2017
|
נושאים: | |
גישה מקוונת: | https://hdl.handle.net/10356/80789 http://hdl.handle.net/10220/42255 |
פריטים דומים
-
Aging and the microbiome: implications for asthma in the elderly?
מאת: Chotirmall, Sanjay Haresh, et al.
יצא לאור: (2017) -
Transforming growth factor β and severe asthma: A perfect storm
מאת: Al-Alawi, Mazen, et al.
יצא לאור: (2017) -
Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients
מאת: A. Arrobas, et al.
יצא לאור: (2021-03-01) -
Economic burden of short-acting beta-2 agonist (SABA) overuse among asthma patients in Türkiye: a cost analysis with respect to the updated GINA treatment recommendations
מאת: Arzu Yorgancıoğlu, et al.
יצא לאור: (2024-10-01) -
Economic Evaluation of Mepolizumab as Add-on Therapy to Standard Care in Severe Eosinophilic Asthma: A Cost-Effectiveness Analysis in Colombia
מאת: Buendia JA, et al.
יצא לאור: (2025-02-01)